The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against ·OH-mediated strand breaks

Free Radical Biology and Medicine

Volumn 25, Issue 8, 1998, Pages 875-880

  Hermes Lima, Marcelo ^a,b   Nagy, Eva ^b   Ponka, Prem ^b,c   Schulman, Herbert M ^b,d  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d BioMed Consult and Edit Services   (Canada)

Author keywords

thalassemia; Cancer; Desferrioxamine; DNA Strand break; Free radicals; Iron overload; Plasmid; Pyridoxal isonicotinoyl hydrazone

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; DEOXYRIBOSE; HYDRAZONE DERIVATIVE; HYPOXANTHINE; IRON; PYRIDOXAL BENZOYLHYDRAZONE; SALICYLALDEHYDE ISONICOTINOYLHYDRAZONE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; ARTICLE; AUTOOXIDATION; CANCER; DNA DAMAGE; DRUG STRUCTURE; IRON CHELATION; IRON OVERLOAD; PRIORITY JOURNAL;

ANTIOXIDANTS; DNA DAMAGE; FERROUS COMPOUNDS; HYDROXYL RADICAL; HYPOXANTHINE; IRON CHELATING AGENTS; ISONIAZID; OXIDATION-REDUCTION; PLASMIDS; PYRIDOXAL; XANTHINE OXIDASE;

EID: 0032533742     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(98)00117-8     Document Type: Article

References (37)

1. Ponka P., Borova J., Neuwirt J., Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 97:1979;317-321.
2. Ponka P., Borova J., Neuwirt J., Fuchs O., Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta. 586:1979;278-297.
3. Ponka P., Grandy R.W., Wilczynska A., Schulman H.M. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone. Biochim. Biophys. Acta. 802:1984;477-489.
4. Ponka P. Physiology and pathophysiology of iron metabolism Implications for iron chelation therapy in iron overload . Bergeron J.J.M., Brittenham G.M. The development of iron chelators for clinical use. 1994;1-32 CRC Press, Boca Raton.
5. Blaha K., Cikrt M., Nerudova J., Fornuskova H., Ponka P. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood. 91:1998;4368-4372.
6. Pippard M.J. Secondary iron overload. Brock J. H., Halliday J.W., Pippard M.J., Powell L.W. Iron metabolism in health and disease. 1994;271-309 W.B. Sauders Company Ltd, London.
7. Webb, J., Vitolo, M. L. Pyridoxal isonicotinoyl hydrazone (PIH): A promising new iron chelator. In: Fucharoen, S.; Rowley, P. T.; Paul, N. W. Birth defects: original article series, vol. 23, no. 5B. March of Dimes Birth Defects Foundation; 1988:63-70.
8. Pippard, M. J. Clinical use of iron chelation. In: de Sousa, M., Brock, J. H., eds. Cancer and inflammation. John Wiley and Sons Ltd.; 1989:361-392.
9. Hershko C. Iron chelators. Brock J.H., Halliday J.W., Pippard M.J., Powell L.W. Iron metabolism in health and disease. 1994;391-426 W.B. Saunders Company Ltd, London.
10. Brittenham G.M. Pyridoxal isonicotinoyl hydrazone an effective iron chelator after oral administration . Semin. Hematol. 27:1990;112-116.
11. Brittenham G.M. Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration. Ann. NY Acad. Sci. 612:1990;315-326.
12. Richardson D.R., Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues potential orally effective iron chelating agents for the treatment of iron overload disease . J. Lab. Clin. Med. 131:1998;306-315.
13. Britton R.S., Bacon B.R., Tavill A.S. Mechanisms of iron toxicity. Brock J.H., Halliday J.W., Pippard M.J., Powell L.W. Iron metabolism in health and disease. 1994;311-351 W.B. Saunders Company Ltd, London.
14. Halliwell B., Gutteridge J. Role of free radicals and catalytic metal ions in human disease. Meth. Enzymol. 186:1990;1-85.
15. Toyokuni S., Sagripanti J.L. Induction of oxidative single- and double-strand breaks in DNA by ferric citrate. Free Radic. Biol. Med. 15:1993;117-123.
16. Dabbagh A.J., Mannion T., Lynch S.M., Frei B. The effect of iron overload on rat plasma and liver oxidant status in vivo. Biochem. J. 300:1994;799-803.
17. Toyokuni, S.; Uchida, K.; Okamoto, K.; Hattori-Nakakuki; Hiai, H.; Stadtman, E. R. Formation of 4-hydroxy-2-nonenol-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc. Natl. Acad. Sci. USA91:2616-2620; 1994.
18. Hermes-Lima M., Castilho R.F., Meinicke A.R., Vercesi A.E. Characteristics of Fe(II) ATP complex-induced damage to the rat liver mitochondrial membrane. Mol. Cell. Biochem. 145:1995;53-60.
19. Toyokuni S. Iron-induced carcinogenesis The role of redox regulation . Free Radic. Biol. Med. 20:1996;553-566.
20. Meneghini R. Iron homeostasis, oxidative stress, and DNA damage. Free Radic. Biol. Med. 23:1997;783-792.
21. Ammann R.W., Muller E., Bansky J., Schuler G., Hacki W.H. High incidence of extrahepatic carcinomas in idiopathic hemochromatosis. Scand. J. Gastroenterol. 15:1980;733-736.
22. Tiniakos G., Wiliams R. Cirrhotic process, liver cell carcinoma and extrahepatic malignant tumors in idiopathic hemochromatosis. Study of 71 patients treated with venesection therapy. Appl. Pathol. 6:1988;128-138.
23. Niederau C., Fisher R., Purschel A., Stremmel W., Haussinger D., Strohmeyer G. Long-term survival in patients with hereditary hemochro matosis. Gastroenterology. 110:1996;1107-1119.
24. Li J.-L., Okada S., Hamazaki S., Ebina Y., Midorikawa O. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res. 47:1987;1867-1869.
25. Schulman H.M., Hermes-Lima M., Wang E.M., Ponka P. In vitro antioxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and some of its analogs. Redox Report. 1:1995;373-378.
26. Bhattacharya M., Ponka P., Hardy P., Hanna N., Varma D.R., Lachapelle P., Chemtob S. Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone. Free Radic. Biol. Med. 22:1997;11-16.
27. Edward J.T., Gauthier M., Chubb F.L., Ponka P. Synthesis of new acyl hydrazones as iron chelating compounds. J. Chem. Eng. Data. 33:1988;538-540.
28. Lloyd R.S., Haidle C.W., Robberson D.L. Bleomycin-specific fragmentation of double-stranded DNA. Biochemistry. 17:1978;1890-1896.
29. Ribeiro D.T., Madzak C., Sarasin A., Di Mascio P., Sies H., Menck C.F.M. Singlet oxygen induced DNA damage and mutagenicity in a single stranded SV40-based shuttle vector. Photochem. Photobiol. 55:1992;39-45.
30. Hermes-Lima M., Wang E.M., Schulman H.M., Storey K.B., Ponka P. Deoxyribose degradation by Fe(III)-EDTA kinetic aspects and potential usefulness for sub-micromolar iron measurements . Mol. Cell Biochem. 137:1994;65-73.
31. Klein S.M., Cohen G., Cederbaum A.I. Production of formaldehyde during metabolism of dimethyl sulfoxide by hydroxyl radical generating system. Biochemistry. 20:1981;6006-6012.
32. Hoe S., Rowley D.A., Halliwell B. Reactions of ferrioxamine and desferrioxamine with the hydroxyl radical. Chem. Biol. Interact. 41:1982;75-81.
33. ·OH-mediated strand breaks to plasmid pUC-18 DNA. Second Annual Meeting of the Oxygen Society, Pasadena, CA, Abstract 1-54; 1995.
34. Aust S.D., Morehouse L.A., Thomas C.E. Role of metals in oxygen radical reactions. J Free Radic. Biol. Med. 1:1985;3-25.
35. Reif D.W. Ferritin as a source of iron for oxidative damage. Free Radic. Biol. Med. 12:1992;417-427.
36. Burkitt M.J., Milne L., Tsang S.Y., Tam S.C. Calcium indicator dye Quin 2 inhibits hydrogen peroxide-induced DNA strand break formation via chelation of iron. Arch. Biochem. Biophys. 311:1994;321-328.
37. Richardson D.R., Wis Vitolo M.L., Hefter G.T., May P.M., Clare B.W., Webb J., Wilairat P. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionization characteristics of the ligands and their relevance to biological properties. Inorg. Chim. Acta. 170:1990;165-170.